Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Non-Insulin Therapies For Diabetes Market Expected To Reach $28.39 Billion By 2030 At 5.9% CAGR
The market for diabetes treatments that do not involve insulin has experienced robust expansion lately, projecting a climb from $21.21 billion in 2025 to $22.59 billion in 2026, driven by a compound annual growth rate of 6.5%. Key factors fueling this expansion historically include the widespread incidence of type 2 diabetes, a considerable dependence on oral medications to lower blood sugar, challenges with patient compliance regarding insulin regimens, an increase in distribution channels within hospitals and retail pharmacies, and the introduction of various new therapeutic categories.
The realm of non-insulin treatments for diabetes is poised for considerable expansion, projecting to reach a valuation of $28.39 billion by the year 2030. This impressive upward trajectory is underpinned by a compound annual growth rate of 5.9%. Key drivers fueling this expansion over the projected timeframe encompass the escalating uptake of combined non-insulin drug regimens, a heightened reliance on GLP-1 and SGLT2 inhibitors, the broadening reach of online pharmaceutical services, the increasing prevalence of tailored and precision medicine strategies, and the ongoing advancements in integrating digital health platforms with remote patient monitoring capabilities. Furthermore, significant prevailing trends anticipated within this period include a growing emphasis on individualized diabetes care plans, a more widespread application of AI-powered systems for glucose level tracking, enhanced integration of telemedicine-connected therapeutic solutions, the accelerated implementation of data-informed clinical decision support mechanisms, and the progressive deployment of interconnected devices designed to facilitate remote patient management.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16494&type=smp
Non-Insulin Therapies For Diabetes Market Growth Factors: Which Forces Are Supporting Market Expansion?
With the escalating global incidence of diabetes, a significant expansion of the non-insulin therapies segment within the diabetes market is anticipated. Diabetes, a long-term health issue defined by elevated blood glucose levels, arises when the body’s capacity to produce or effectively utilize insulin is compromised. Factors contributing to this rise include inactive lifestyles, poor dietary habits, hereditary factors, an aging demographic, increased obesity rates, ethnic predispositions, insufficient public knowledge, restricted healthcare accessibility, and various environmental influences. These non-insulin treatments aid in managing diabetes by enhancing the body’s response to insulin, curbing glucose synthesis in the liver, facilitating glucose absorption by muscle tissues, and generally improving blood sugar regulation. Illustrating this trend, the UK’s Office for Health Improvement & Disparities reported in March 2024 that the documented prevalence of type 2 diabetes among individuals aged 17 and above had climbed to 7.0%, an increase from the 6.8% recorded in March 2023. Consequently, the growing prevalence of diabetes is a direct catalyst for the expansion of the non-insulin diabetes therapeutics market.
Non-Insulin Therapies For Diabetes Market Segment Breakdown: Which Categories Generate The Most Revenue?
The non-insulin therapies for diabetes market covered in this report is segmented –
1) By Type: Biguanides, Sulfonylureas, Thiazolidinediones (TZDs), DPP 4 Inhibitors, GLP 1 Analogs Or Agonists, SGLT2 Inhibitors
2) By Route Of Administration: Oral, Injectable
3) By Application: Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals Or Clinics, Homecare Or Patients, Other End-Users
Subsegments:
1) By Biguanides: Metformin, Combination Of Metformin With Other Drugs
2) By Sulfonylureas: Glimepiride, Glipizide, Glyburide
3) By Thiazolidinediones (TZDs): Pioglitazone, Rosiglitazone
4) By DPP 4 Inhibitors: Sitagliptin, Saxagliptin, Linagliptin
5) By GLP 1 Analogs Or Agonists: Exenatide, Liraglutide, Dulaglutide
6) By SGLT2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin
Non-Insulin Therapies For Diabetes Market Industry Trends: What Changes Are Reshaping Demand?
Companies at the forefront of the non-insulin diabetes therapies sector are prioritizing innovation, particularly through the creation of sophisticated treatments like non-insulin GLP-1 receptor agonists. This strategic direction aims to broaden therapeutic avenues, enhance blood sugar management, and solidify their standing within the broader field of diabetes and obesity care. The advent of non-insulin GLP-1 receptor agonists signifies the rollout of treatments designed to influence GLP-1 receptors, thereby aiding in both blood sugar regulation and weight management, independent of insulin. Illustrating this trend, Eli Lilly and Company, a prominent American pharmaceutical firm with a distinct focus on diabetes and metabolic treatments, introduced Mounjaro (tirzepatide) to the Indian market in March 2025, subsequent to receiving clearance from the Central Drugs Standard Control Organisation. Mounjaro, which functions as a combined GIP and GLP-1 receptor agonist, tackles prevalent issues in managing type 2 diabetes and obesity by offering the convenience of a once-weekly subcutaneous injection. This novel approach contributes to improved glycemic control, appetite suppression, delayed stomach emptying, and substantial weight loss, with initial dosage strengths of 2.5 mg and 5 mg available to foster better patient compliance and foster positive long-term results.
Non-Insulin Therapies For Diabetes Market Key Players And Strategic Industry Positioning
Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC
Access The Complete Non-Insulin Therapies For Diabetes Market Report:
Non-Insulin Therapies For Diabetes Market Largest Region: Which Geography Holds The Highest Market Share?
North Americawas the largest region in the non-insulin therapies for diabetes market in 2025. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model